Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses

References

• FalkaiPWobrockTLiebermanJWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophreniaWorld J Biol Psychiatry2006754016509050
   PubMed Web of Science ®Google Scholar
• KaneJMLeuchtSCarpenterDExpert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic DisordersThe expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summaryJ Clin Psychiatry200364Suppl 12S5S19
   PubMed Web of Science ®Google Scholar
• NasrallahHAThe case for long-acting antipsychotic agents in the post-CATIE eraActa Psychiatr Scand200711526026717355516
   PubMed Web of Science ®Google Scholar
• KaneJMStrategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studiesJ Clin Psychiatry200364Suppl 16S34S40
   PubMed Web of Science ®Google Scholar
• PatelMXTaylorMDavidASAntipsychotic long-acting (depot) injections for the treatment of schizophreniaBr J Psychiatry2009195S1S57
   PubMed Web of Science ®Google Scholar
• TaylorMNgKYShould long-acting (depot) antipsychotics be used in early schizophrenia? A systematic reviewAust N Z J Psychiatry20134762463023209308
   PubMed Web of Science ®Google Scholar
• TiihonenJHaukkaJTaylorMHaddadPMPatelMXKorhonenPA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry201116860360921362741
   PubMed Web of Science ®Google Scholar
• LaurielloJLambertTAndersenSLinDTaylorCCMcDonnellDAn 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophreniaJ Clin Psychiatry20086979079918452346
   PubMed Web of Science ®Google Scholar
• KaneJMDetkeHCNaberDOlanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophreniaAm J Psychiatry201016718118920008947
   PubMed Web of Science ®Google Scholar
• DetkeHWeidenPJLambertTOlanzapine long-acting injection vs oral olanzapine in schizophrenia outpatients: a 2-year, randomized, open-label studyEur Neuropsychopharmacol201020S464
   Web of Science ®Google Scholar
• ClinicalTrials.govOlanzapine pamoate depot versus oral olanzapine on treatment outcomes in outpatients with schizophrenia Available from: http://clinicaltrials.gov/show/NCT00320489Accessed January 31, 2013
   Google Scholar
• LiebermanJAStroupTSMcEvoyJPClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) InvestigatorsEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med20053531209122316172203
   PubMed Web of Science ®Google Scholar
• KahnRSFleischhackerWWBoterHEUFEST Study GroupEffectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialLancet20083711085109718374841
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHMontgomeryWSMcDonnellDPColemanKAFeldmanPDTreatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisonsInt J Gen Med2012539139822615534
   PubMedGoogle Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull1987132612763616518
   PubMed Web of Science ®Google Scholar
• GuyWECDEU Assessment Manual for PsychopharmacologyWashington, DCUS Department of Health, Education and Welfare1976
   Google Scholar
• BarnesTRA rating scale for drug-induced akathisiaBr J Psychiatry19891546726762574607
   PubMed Web of Science ®Google Scholar
• SimpsonGMAngusJWA rating scale for extrapyramidal side effectsActa Psychiatr Scand Suppl197021211194917967
   PubMedGoogle Scholar
• TiihonenJWahlbeckKLönnqvistJEffectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up studyBMJ200633322416825203
   PubMed Web of Science ®Google Scholar
• BeasleyCMJrStaufferVLLiu-SeifertHTaylorCCDunayevichEDavisJMAll-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysisJ Clin Psychopharmacol20072725225817502771
   PubMed Web of Science ®Google Scholar
• LeuchtSKomossaKRummel-KlugeCA meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophreniaAm J Psychiatry200916615216319015230
   PubMed Web of Science ®Google Scholar
• LeuchtSCorvesCArbterDEngelRRLiCDavisJMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisLancet2009373314119058842
   PubMed Web of Science ®Google Scholar
• Olanzapine long-acting injectionSummary of Product Characteristics7112012 Available from: http://www.medicines.org.uk/EMC/medicine/21361/SPC/ZYPADHERA+210+mg%2c+300+mg%2c+and+405+mg%2c+powder+and+solvent+for+prolonged+release+suspension+for+injection/Accessed February 8, 2013
   Google Scholar
• OlanzapineSummary of Product Characteristics7112012 Available from: http://www.medicines.org.uk/EMC/medicine/614/SPC/Zyprexa++2.5mg%2c+5mg%2c+7.5mg%2c+10mg%2c+15mg%2c++and+20mg+coated+tablets.+Zyprexa+Velotab++5mg%2c+10mg%2c+15mg%2c++and+20mg++orodispersible+tablets/Accessed February 8, 2013
   Google Scholar
• NovickDHaroJMBertschJHaddadPMIncidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes studyJ Clin Psychopharmacol20103053154020814320
   PubMed Web of Science ®Google Scholar
• KomossaKRummel-KlugeCHungerHOlanzapine versus other atypical antipsychotics for schizophreniaCochrane Database Syst Rev20103CD00665420238348
   PubMed Web of Science ®Google Scholar
• KrzystanekMKrupka-MatuszczykIAn open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapineHum Psychopharmacol201126818523055416
   PubMed Web of Science ®Google Scholar
• BusheCJSlooffCJHaddadPMKaragianisJLWeight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes DatabaseJ Psychopharmacol20132735836523343595
   PubMed Web of Science ®Google Scholar
• HillALSunBKaragianisJLWatsonSBMcDonnellDPDose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophreniaBMC Psychiatry2011112821324135
   PubMed Web of Science ®Google Scholar